Mode
Text Size
Log in / Sign up
N/A N=12 Randomized Triple-blind Supportive Care

Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease

Parkinson Disease

Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Functional Ambulation Profile (FAP) Score — 99.2; 86.8 FAP score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Vibration Session (Device); No vibration session (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Virginia Commonwealth University
Primary completion
Jan 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Functional Ambulation Profile (FAP) Score
99.2; 86.8
PRIMARY
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS)
14.1; 12.8; 14.0; 13.0; 34.6; 37.0
SECONDARY
Timed Up and Go (TUG) Test
10.5; 10.4; 10.7; 10.9
SECONDARY
Berg Balance Scale (BBS)
50.4; 51.4; 51.4; 52.1
SECONDARY
New Freezing of Gait Questionnaire (nFOG-Q)
10.0; 8.7; 8.2; 9.0
SECONDARY
Fall Efficacy Scale - International
29.2; 8.7; 28.7; 28.4

Summary

The purpose of this research study is to test the safety, tolerability, and the effect of vibration (delivered by an experimental device called PDVibe2) on freezing of gait (FOG) in persons with Parkinson's disease (PD). The PDVibe2 was developed by Resonate Forward, LLC (RF). This PDVibe2 was designed to administer vibration therapy to the wearer to improve gait and balance in persons with PD while wearing the device.

Eligibility Criteria

Inclusion criteria

  • age 21 years or older
  • PD diagnosed by a movement disorder specialist for 3 months or longer prior to recruitment
  • PD medication regimen is stable over the last 3 months with no changes
  • Hoehn & Yahr stage 2 (N = 13)
  • able to walk independently or with a simple assistive device (e.g., cane, walker)
  • observed by the research team to have PD related gait disturbance such as FOG, shortened or irregular stride lengths, irregular step cadence, slowed speed while on their regular treatment regimen.

Exclusion Criteria

  • diagnosed with a known Parkinson plus syndrome
  • were previously exposed to vibration treatment for gait and balance
  • presence of dementia (Montreal Cognitive Assessment < 21)
  • additional disorders (not related to PD)impairing gait, stance, balance or coordination (e.g. stroke, leg amputations, or multiple sclerosis)
  • history of implantable cardiac device or any other implanted electronic device except a deep brain stimulator (DBS)
  • use of braces/orthotics that assist with walking
  • are currently in physical therapy (PT) treatment for balance or gait
  • peripheral neuropathy by exam
  • any condition that, in the opinion of the PIs, would compromise participant safety, data integrity, or data interpretation.
  • Children under the age of 18
  • Prisoners
  • Women who are pregnant or may become pregnant during the course of this study since the safety of this device for an unborn child is unknown.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03883217). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search